The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review
GastroenterologiaSobre o estudo
- Desenho
- Revisão sistemática
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Cancer treatment reviews
- Publicado em
- 12 jan 2024
- Citações
- 21
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review
Davide Ciardiello, Gianluca Mauri, Andrea Sartore-Bianchi, Salvatore Siena, Maria Giulia Zampino, Nicola Fazio, Andrés Cervantes
Descritores MeSH
- Colonic Neoplasms
- Colorectal Neoplasms
- Rectal Neoplasms
- Retrospective Studies
- Cetuximab
- Proto-Oncogene Proteins B-raf
- Antibodies, Monoclonal
- Humans
Veja também
Estudos relacionados
- Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database
- Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
- Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes
- A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis